Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Reyataz 150 Mg Caps 60 By Bristol-Myers

Image 0 of Reyataz 150 Mg Caps 60 By Bristol-Myers Image 1 of Reyataz 150 Mg Caps 60 By Bristol-Myers

Reyataz 150 Mg Caps 60 By Bristol-Myers

CALL US FOR THE PRICE

Reyataz 150 Mg Caps 60 By Bristol-Myers. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3503935/RXB10053886/RXA322254
Size : 60
Selling UoM : EA
NDC: 00003-3624-12
UPC Barcode : 300033624120
Supplier: 0050001077 BRISTOL-MYERS SQUIBB
Supplier Material : 362412
Generic Code : 052747 ATAZANAVIR SULFATE ORAL CAPSULE 150 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  CALL US FOR THE PRICE

Product Description.:

BMS 150mg, 3624
capsule , blue , oblong oblong
white and blue ink

REYATAZ? (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease.

The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13pentaazatetradecanedioic acid dimethyl ester, sulfate (1:1). Its molecular formula is C38H52N6O7?H2SO4, which corresponds to a molecular weight of 802.9 (sulfuric acid salt).

Atazanavir sulfate is a white to pale yellow crystalline powder. It is slightly soluble in water (4-5 mg/mL, free base equivalent) with the pH of a saturated solution in water being about 1.9 at 24 ? 3? C.

REYATAZ Capsules are available for oral administration in strengths containing the equivalent of 100 mg, 150 mg, 200 mg, or 300 mg of atazanavir as atazanavir sulfate and the following inactive ingredients: crospovidone, lactose monohydrate, and magnesium stearate. The capsule shells contain the following inactive ingredients: gelatin, FD&C Blue #2, titanium dioxide, black iron oxide, red iron oxide, and yellow iron oxide. The capsules are printed with ink containing shellac, titanium dioxide, FD&C Blue #2, isopropyl alcohol, ammonium hydroxide, propylene glycol, n-butyl alcohol, simethicone, and dehydrated alcohol.

INDICATIONS

REYATAZ? (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age.

* The following points should be considered when initiating therapy with REYATAZ:
* In Study AI424-045 REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection [see Clinical Studies].

The number of baseline primary protease inhibitor mutations affects the virologic response to REYATAZ/ritonavir

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

* cardiac conduction abnormalities [see WARNINGS AND PRECAUTIONS]
* rash [see WARNINGS AND PRECAUTIONS]
* hyperbilirubinemia [see WARNINGS AND PRECAUTIONS]
* nephrolithiasis [see WARNINGS AND PRECAUTIONS]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trial Experience in Adults
Treatment-Emergent Adverse Reactions in Treatment-Naive Patients

The safety profile of REYATAZ in treatment-naive adults is based on 1625 HIV-1 infected patients in clinical trials. 536 patients received REYATAZ 300 mg with ritonavir 100 mg and 1089 patients received REYATAZ 400 mg or higher (without ritonavir).

The most common adverse reactions are nausea, jaundice/scleral icterus, and rash.